{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:28:54Z","timestamp":1740144534506,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Even though frequent, it is not known how HIV infection and treatment impact in the consolidation by radiotherapy of non-Hodgkin diffuse large B-cell lymphomas (DBCL). This article aim to assess that difference that HIV makes on radiation treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Patients and methods<\/jats:title>\n<jats:p>A retrospective cohort of all DBCL patients treated with chemotherapy and consolidative radiotherapy at a single institution between 2010 and 2018 was assessed. All patients had biopsy-proven lymphoma and were included if radiation was part of the treatment and had at least 6\u2009months of follow-up or were followed until death.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Three-hundred fifty-nine (359) patients were selected, with a median age at diagnosis of 57.7\u2009years (13\u201390\u2009years). Twenty-eight patients (7.8%) were HIV positive. Median follow-up was 48.0\u2009months. Female patients were 51.3% and most had a good performance in the ECOG scale (78.8% are ECOG 0\u20131). Median overall survival was not reached, but mean OS was 50.1\u2009months with 86 deaths. Median progression-free survival was 48.7\u2009months. HIV infection had no impact on OS (<jats:italic>p<\/jats:italic>\u00a0=\u20090.580) or PFS (<jats:italic>p<\/jats:italic>\u00a0=\u20090.347) among patients treated with RT. HIV positive patients were more frequently staged only with CT (<jats:italic>p<\/jats:italic>\u00a0&gt;\u20090.05) with no impact on PFS (<jats:italic>p<\/jats:italic>\u00a0=\u20090.191). No HIV positive patient received rituximab due to local policy restrictions and HIV positive patients were more prone to receive CHOP-like chemotherapy (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.05), specially ones with etoposide (CHOEP). CHOP was associated with better survival (<jats:italic>p<\/jats:italic>\u00a0=\u20090.015) in the overall population and in the HIV negative population (<jats:italic>p<\/jats:italic>\u00a0=\u20090.002), but not in the HIV positive population (<jats:italic>p<\/jats:italic>\u00a0=\u20090.982). RT toxicities were not overall more frequent in the HIV positive population (<jats:italic>p<\/jats:italic>\u00a0=\u20090.567), except for fatigue (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.05) and hematological toxicities (<jats:italic>p<\/jats:italic>\u00a0=\u20090.022).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>HIV status did not influence on survival when patients were treated with consolidative radiotherapy. HIV infection was a bias on our sample for staging methods and chemotherapy regimens choices. For HIV positive patients there was an increase in fatigue and hematological toxicities of any grade with radiation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-01589-1","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T14:03:46Z","timestamp":1592229826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Carolina Trindade Mello","family":"Medici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-3110","authenticated-orcid":false,"given":"Geovanne Pedro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Coelho","family":"Casimiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"issue":"5","key":"1589_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1589_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381. https:\/\/doi.org\/10.1182\/blood-2017-07-793984.","journal-title":"Blood"},{"key":"1589_CR3","doi-asserted-by":"publisher","unstructured":"Pfreundschuh, Michael, et al. \"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA.\" (2018): 7574\u20137574. DOI: https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7574 Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 7574\u20137574.","DOI":"10.1200\/JCO.2018.36.15_suppl.7574"},{"issue":"3","key":"1589_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","volume":"100","author":"AK Ng","year":"2018","unstructured":"Ng AK, et al. Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiation Oncol Biol Physics. 2018;100(3):652\u201369. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.005.","journal-title":"Int J Radiation Oncol Biol Physics"},{"issue":"18","key":"1589_CR5","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","volume":"31","author":"C Besson","year":"2017","unstructured":"Besson C, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids. 2017;31(18):2493\u2013501. https:\/\/doi.org\/10.1097\/QAD.0000000000001652.","journal-title":"Aids"},{"issue":"18","key":"1589_CR6","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","volume":"65","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 2005;65(18):8256\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1220.","journal-title":"Cancer Res"},{"issue":"2","key":"1589_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/cncr.24878","volume":"116","author":"N Housri","year":"2010","unstructured":"Housri N, Yarchoan R, Kaushal A. Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary? Cancer. 2010;116(2):273\u201383. https:\/\/doi.org\/10.1002\/cncr.24878.","journal-title":"Cancer"},{"issue":"6","key":"1589_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjh.14489","volume":"176","author":"C Montalb\u00e1n","year":"2017","unstructured":"Montalb\u00e1n C, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b22-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918\u201328. https:\/\/doi.org\/10.1111\/bjh.14489.","journal-title":"Br J Haematol"},{"issue":"3","key":"1589_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253\u201364. https:\/\/doi.org\/10.1016\/S1473-3099(19)30036-2.","journal-title":"Lancet Infect Dis"},{"key":"1589_CR10","doi-asserted-by":"publisher","unstructured":"Sathekge M, et al. FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Quarterly J Nuclear Med Mole Imaging. 54(6, 2010):698. https:\/\/doi.org\/10.1007\/s00259-012-2115-y.","DOI":"10.1007\/s00259-012-2115-y"},{"issue":"12","key":"1589_CR11","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","volume":"101","author":"RF Little","year":"2003","unstructured":"Little RF, et al. Highly effective treatment of acquired immunodeficiency syndrome\u2013related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653\u20139. https:\/\/doi.org\/10.1182\/blood-2002-11-3589.","journal-title":"Blood"},{"issue":"8","key":"1589_CR12","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15(8):2945\u201353. https:\/\/doi.org\/10.1200\/JCO.1997.15.8.2945.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01589-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T23:09:26Z","timestamp":1623712166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01589-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"type":"electronic","value":"1748-717X"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was submitted to local ethics committee and consent was given in June 2018. We were granted a waiver to request each patient consent due to it\u2019s a retrospective study by the ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author grants the publisher the sole and exclusive license of the full copyright. The authors guarantee that this manuscript has not been previously published elsewhere. The authors declare that any person named as co-author of the contribution is aware of the fact and has agreed to being so named.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not have any conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}